Dendritic Cells and Their Role in Immunotherapy

Gardner, Alycia; Pulido, Álvaro de Mingo; Ruffell, Brian

doi:10.3389/fimmu.2020.00924

Cited by 274 publications

(164 citation statements)

References 148 publications

(175 reference statements)

Supporting

Mentioning

161

Contrasting

Unclassified

Order By: Relevance

“…cDC1 is primarily defined by the transcription factors BATF3 and IRF8. Type 1 cDCs are also defined by cell-surface expression of CD8α and CD103, with CD8α + cDC1s considered to be lymphoid organ-resident cDC1s, and CD103 + cDC1s considered to be tissue-resident or migratory cDC1s ( 5 ). cDC2 is frequently defined by the transcription factor IRF4 and surface expression of CD11b, CD1c, and SIRPα ( 5 ).…”

Section: Conventional Dcs (Cdcs)mentioning

confidence: 99%

“…Whereas cDCs and pDCs are derived from common DC progenitors, these subsets possess considerably different characteristics and functions ( 5 ). As mentioned above, antigen presentation is the main role of cDCs.…”

Section: Plasmacytoid Dcs (Pdcs)mentioning

confidence: 99%

“…During inflammatory responses, Ly6C + (mouse) or CD14 + (human) monocytes migrate into the inflammatory site and differentiate into DCs called monocyte-derived DCs (moDCs) ( Fig. 1B ) ( 4 , 5 ). Monocytes in the blood directly migrate into dLNs and differentiate into CD11c + CD11b hi Gr-1 + moDCs after initiation of the inflammatory response to produce IL-12 and stimulate Th1 responses ( 48 ).…”

Section: Monocyte-derived Dcs (Modcs)mentioning

confidence: 99%

“…Therefore, controlling DC activity has considerable potential in improving antitumor immunity ( 4 ). Many therapies that manipulate the activation, migration, and function of DCs have undergone clinical trials ( 5 ). Furthermore, recent studies have reported the importance of DCs in cancer therapies, such as radiation therapy, chemotherapy, adoptive cell therapy, and immune-checkpoint blockade.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The role of dendritic cells in tumor microenvironments and their uses as therapeutic targets

Kim

Lee

2021

BMB Rep.

View full text Add to dashboard Cite

Dendritic cells (DC), which consist of several different subsets, specialize in antigen presentation and are critical for mediating the innate and adaptive immune responses. DC subsets can be classified into conventional, plasmacytoid, and monocyte-derived DC in the tumor microenvironment, and each subset plays a different role. Because of the role of intratumoral DCs in initiating antitumor immune responses with tumor-derived antigen presentation to T cells, DCs have been targeted in the treatment of cancer. By regulating the functionality of DCs, several DC-based immunotherapies have been developed, including administration of tumor-derived antigens and DC vaccines. In addition, DCs participate in the mechanisms of classical cancer therapies, such as radiation therapy and chemotherapy. Thus, regulating DCs is also important in improving current cancer therapies. Here, we will discuss the role of each DC subset in antitumor immune responses, and the current status of DC-related cancer therapies.

show abstract

Section: Conventional Dcs (Cdcs)mentioning

confidence: 99%

Section: Plasmacytoid Dcs (Pdcs)mentioning

confidence: 99%

Section: Monocyte-derived Dcs (Modcs)mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The role of dendritic cells in tumor microenvironments and their uses as therapeutic targets

Kim

Lee

2021

BMB Rep.

View full text Add to dashboard Cite

show abstract

“…Sometimes, the DCs are fused to BC cells in vaccine production [ 76 , 77 ]. Moreover, adjuvants such as IL-12, IFN-γ, lipopolysaccharides (LPS), and other cocktails are used to induce a mature DC phenotype [ 78 , 79 , 80 , 81 , 82 ]. These pulsed and primed DCs are then inoculated back into the patient or animal model as a vaccine.…”

Section: Myeloid Cellsmentioning

confidence: 99%

The Role of the Tumor Microenvironment in Developing Successful Therapeutic and Secondary Prophylactic Breast Cancer Vaccines

Gordon

Gadi

2020

Vaccines

View full text Add to dashboard Cite

Breast cancer affects roughly one in eight women over their lifetime and is a leading cause of cancer-related death in women. While outcomes have improved in recent years, prognosis remains poor for patients who present with either disseminated disease or aggressive molecular subtypes. Cancer immunotherapy has revolutionized the treatment of several cancers, with therapeutic vaccines aiming to direct the cytotoxic immune program against tumor cells showing particular promise. However, these results have yet to translate to breast cancer, which remains largely refractory from such approaches. Recent evidence suggests that the breast tumor microenvironment (TME) is an important and long understudied barrier to the efficacy of therapeutic vaccines. Through an improved understanding of the complex and biologically diverse breast TME, it may be possible to advance new combination strategies to render breast carcinomas sensitive to the effects of therapeutic vaccines. Here, we discuss past and present efforts to advance therapeutic vaccines in the treatment of breast cancer, the molecular mechanisms through which the TME contributes to the failure of such approaches, as well as the potential means through which these can be overcome.

show abstract

Prognostic association of immunoproteasome expression in solid tumours is governed by the immediate immune environment

et al. 2023

View full text Add to dashboard Cite

Induction of immunoproteasome (IP) expression in tumour cells can enhance antigen presentation and immunogenicity. Recently, the overexpression of IP genes has been associated with better prognosis and response to immune checkpoint blockade (ICB) therapies in melanoma. However, the extent of this association in other solid tumours and how that is influenced by tumour cell‐intrinsic and cell‐extrinsic factors remain unclear. Here, we address this by exploring the gene expression patterns from available bulk and single‐cell transcriptomic data of primary tumours. We find that tumours with high‐IP expression exhibit cytotoxic immune cell infiltration and upregulation of IFN‐γ and TNF‐α pathways in tumour cells. However, the association of IP expression with overall survival (TCGA cohort) and response to ICB therapy (non‐TCGA cohorts) is tumour‐type specific (better in non‐small‐cell lung, breast, bladder and thymus; and worse in glioma and renal) and is greatly influenced by pro‐ or antitumourigenic immune cell infiltration patterns. This emphasises the need for considering immune cell infiltration patterns, along with IP expression, as a prognostic biomarker to predict overall survival or response to ICB therapies in solid tumours, besides melanoma.

show abstract

Dendritic Cells and Their Role in Immunotherapy

Cited by 274 publications

References 148 publications

The role of dendritic cells in tumor microenvironments and their uses as therapeutic targets

The role of dendritic cells in tumor microenvironments and their uses as therapeutic targets

The Role of the Tumor Microenvironment in Developing Successful Therapeutic and Secondary Prophylactic Breast Cancer Vaccines

Prognostic association of immunoproteasome expression in solid tumours is governed by the immediate immune environment

Contact Info

Product

Resources

About